The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Join the Hive!

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

UN agencies launch emergency plan for millions of Venezuelan refugees and migrants

“TTIP can boost the European project”; the Sting reports live from EBS 2015 on TTIP

Who would pay and who is to gain from the EU-US free trade agreement

Mine ban agreement ‘has saved countless lives’, but ‘accelerated efforts’ needed to end scourge for good: Guterres

Quashing myths on 2019-nCoV for better public management

Why trade wars have no winners

Women in Switzerland have gone on strike – this is why

Act now to prevent Desert Locust catastrophe in Horn of Africa: UN agencies

Can climate change wait for the US to rejoin the Paris agreement?

High internet taxes are restricting access and slowing economic growth

‘Real change’ involving women in peace and security, still too slow, Guterres tells Security Council

SRHR and ending HIV: Can one be achieved without the other?

Paris agreed with Berlin over a loose and ineffective banking union

How we can survive the great COVID lockdown: IMF Chief Economist Gita Gopinath

Seaweed, enzymes and compostable cups: Can ‘Big Food’ take on plastic and win?

Making Artificial Intelligence ethical, safe and innovative

State aid: Commission invites comments on simplified rules for State aid combined with EU support

Convincing the Germans to pay also for the unification of Eurozone

5 ways to go green in your own kitchen

No tears for Cyprus in Brussels and Moscow

Secretary-General calls for global participation in UN75 dialogues for better future for all

Parliament approves key directive regulating professional qualifications

EU confronts environmental threats as global leaders attempt to revive the global sentiment at NYC climate week

Google’s hot summer never ends: EC to launch ANOTHER antitrust inquiry against the American giant

Iran: BBC and other broadcast journalists harassed; families threatened – UN experts

Pharmaceuticals spend millions to push TTIP while consumer groups spend peanuts

EU Budget 2019: focus on the young, on migration and innovation

Health spending set to outpace GDP growth to 2030

Fossil fuel support is rising again in a threat to climate change efforts

Coronavirus: Commission starts testing interoperability gateway service for national contact tracing and warning apps

Here’s how the EU is doing on gender equality

How a different kind of investment could transform Latin America

The price of centralization of human resources for health

In the United States, there aren’t enough hours in the week to make rent

EU to give more power to national antitrust authorities in a bid to secure regulatory fines

Two days left until General Data Protection Regulation (GDPR), lots of newsletter opt-outs but does the EU citizen really know?

What are Asia Pacific countries getting right in the fight against cancer?

MEPs call for EU rules to better protect minorities’ rights

EP leaders call for negotiations on upgraded Transparency Register to continue

Boeing subsidy case: World Trade Organization confirms EU right to retaliate against $4 billion of U.S. imports

EU-US Privacy Shield data exchange deal: US must comply by 1 September, say MEPs

Is the European Banking Union an impossible task?

Balancing The Broken See-Saw of Gender Power Dynamics as a Medical Student

The middle-class dream is moving beyond millennial reach

The benefits of a cashless society

EU approves disbursement of €500 million in Macro-Financial Assistance to Ukraine

Sudan: top UN official demands cessation of violence and rape against civilians by security forces

Timor-Leste Foreign Minister highlights value of UN in resolving conflicts

Global Citizen – Volunteer Internships

Fighting Depression In the Isolation of COVID-19

Charges against Baha’i in Yemen must be dropped: UN experts urge release of detainees

Syria: A bloody tracer of Trump – Putin rapprochement

What is true and not true about the new Coronavirus?

Scientists in Iceland are turning carbon dioxide into rock

Be a part of the World Forum on Future Trends in Defence and Security

Hiring more female leaders is good for profits. Here’s the evidence

Lithuania vs Parliament over 2014 EU budget

EU’s guidelines on net neutrality see the light although grey areas do remain

‘A new chapter’ dawns for democracy in Guinea-Bissau: top UN official

6 ways social innovators are harnessing 4IR technologies for social change

More Stings?

Advertising

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Leave a Reply to How to reduce your private medical insurance premium in 6 steps - Nicola Colucci Cancel reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s